Palverafusp alfa

珀维拉芙普α

Report date: 2026/05/07 20:00:36

Base Information

Drug NamePalverafusp alfa
Drug Alias NameIMM-2510SYN-2510AXN-2510
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionVascular endothelial growth factor inhibitorsProgrammed death-ligand 1 blockers
TargetsVascular endothelial growth factorProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Inactive CompaniesAxion Bio IncInstil Bio Inc
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A